Guidance for market authorization requirements for COVID-19 drugs: Quality and manufacturing requirements (English, HTML)

View metadata and access the original English HTML file: Guidance for market authorization requirements for COVID-19 drugs: Quality and manufacturing requirements.

Format

HTML

Access

file-only

Publisher-reported update

2022-07-28

COVID-19 drugs must be manufactured under good manufacturing practices (GMP) conditions. These conditions must be in line with the international requirements outlined in the International Council for Harmonization Q7A guideline and with applicable Health Canada's guidance.

Access original file